Pascal Brandt

Pascal advises companies, financial investors as well as banks on all aspects of capital markets law and financing.

His clients include public companies, international corporates, private equity investors as well as domestic and international financial institutions.

The focus of his practice is on equity and equity-linked transactions as well as bond issuances, including IPOs (also in the context of dual-track processes), capital increases, share placements, block trades, convertible and exchangeable bonds, as well as the issuance of regulatory capital instruments (in particular AT1 and RT1 instruments). In addition, Pascal Brandt regularly advises on financings in connection with M&A transactions, intra-group financing structures and innovative capital markets products, including digital and blockchain-based bonds.

Transactions advised by Pascal include, among others, the spin-off of Siemens Energy and the IPO of Douglas AG as well as the takeover of CureVac by BioNTech. He advised financial institutions on the issuance of (subordinated) capital instruments, including AT1 instruments of Deutsche Bank, Commerzbank and BAWAG Group, RT1 instruments of Allianz, as well as the first blockchain-based digital bond issuances of KfW and NRW.Bank. He has also been involved in numerous acquisition and corporate financings for financial investors and industrial companies, including the acquisition of the Viridium Group by a consortium of leading insurers and asset managers.